Samsung Biologics Participates in DCAT Week in the US to Boost Global Contract Acquisition Efforts
Over 50 Meetings with Global Pharmaceutical Companies in New York
CEO John Rim Attends to Discuss Strategic Partnerships
Continued Participation in International Events Including AACR and PEGS
Samsung Biologics announced on the 25th that it is strengthening its global contract acquisition efforts by participating in "DCAT Week 2026," held in New York, USA from March 23 to 26 (local time).
DCAT Week is a global pharmaceutical and biotechnology networking event that began in 1890 under the auspices of the New York Chamber of Commerce. It is now organized annually by the DCAT Association and is recognized as the optimal event for corporate partnership discussions, as more than 90% of attendees are high-level executives with decision-making authority.
Kevin Sharp, Vice President of Sales and Operations at Samsung Biologics Sales Center, is presenting at the member company announcement forum held on the 23rd (local time). Samsung Biologics
View original imageExcept for 2020, when the event was not held due to COVID-19, Samsung Biologics has participated in DCAT Week for 11 consecutive years since 2016. This year as well, the company has prepared a dedicated meeting room in a prime location at the venue and plans to hold more than 50 business meetings with global pharmaceutical companies. CEO John Rim is also attending the event to discuss strategic partnerships with key industry figures.
On the first day of the event, March 23, Kevin Sharp, Vice President of Sales and Operations at the Samsung Biologics Sales Center, participated as a speaker at the member company announcement forum. Vice President Sharp shared recent achievements under the theme of "Expanding Production Capacity and Network Development," including the acquisition of the Rockville plant, the purchase of the third Bio Campus site, an open innovation partnership with Eli Lilly, and a vaccine production partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).
Samsung Biologics also conducted activities in parallel to enhance brand awareness as a top-tier global contract development and manufacturing organization (CDMO). The company participated as a co-sponsor for a presentation session held the previous day, promoting its CDMO competitiveness before and after the session. In addition, it installed banners and promotional materials at the event venue to further increase brand recognition. At the main DCAT Week dinner event on March 26, Samsung Biologics will join other global CDMO companies such as Lonza and Thermo Fisher Scientific as a sponsor.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In addition to DCAT Week, Samsung Biologics is also scheduled to participate in other major global events, including the American Association for Cancer Research (AACR 2026) Annual Meeting to be held next month in San Diego, USA, and the PEGS Boston Summit taking place in Boston in May.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.